Compare ROP & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROP | KVUE |
|---|---|---|
| Founded | 1981 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 32.9B |
| IPO Year | 2002 | 2023 |
| Metric | ROP | KVUE |
|---|---|---|
| Price | $338.14 | $19.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $492.60 | $19.45 |
| AVG Volume (30 Days) | 1.1M | ★ 19.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | 1.02% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | ★ 4.87 | 0.25 |
| Revenue | $7,902,500,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $8.80 | $4.85 |
| Revenue Next Year | $6.73 | $2.63 |
| P/E Ratio | ★ $68.29 | $75.80 |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $305.96 | $14.02 |
| 52 Week High | $575.77 | $22.87 |
| Indicator | ROP | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 68.85 |
| Support Level | $310.28 | $16.83 |
| Resistance Level | $342.25 | N/A |
| Average True Range (ATR) | 8.72 | 0.34 |
| MACD | 0.90 | 0.12 |
| Stochastic Oscillator | 84.88 | 96.80 |
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.